MRC Technology Launches Respiratory ‘Call for Targets’
News Mar 02, 2015
MRC Technology, an independent life science research charity, today announced a ‘call for targets’ to find new therapeutic concepts for treatment of respiratory disease. The worldwide call to academic researchers offers the opportunity to collaborate with MRC Technology’s Centre for Therapeutic Discovery (CTD) on target validation and proof of concept prior to initiating a full scale drug discovery project. Interested researchers are asked to visit www.callfortargets.org/respiratory.
Through this call MRC Technology aims to identify and accelerate projects focused on validation of potential small molecule or antibody targets, in pathways important in the development or progression of respiratory conditions. Respiratory conditions such as allergy, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis currently affect an estimated 12 million people living in the UK.
The call draws on MRC Technology’s expertise in translating novel, promising biology into lead stage therapeutics. Successful projects will benefit from CTD’s wealth of experience in assay development, high throughput screening (HTS), medicinal chemistry, antibody engineering and affinity maturation. CTD will also provide academic researchers with access to an in-house small molecule library as well as its core antibody humanisation skills.
Justin Bryans, Director of Drug Discovery at MRC Technology, said “MRC Technology’s model is based on sharing both the risks and the rewards of drug discovery with its partners. Finding treatments for respiratory disease is a clear area of unmet need, with COPD being the fifth biggest killer disease in the UK. This latest call for respiratory targets is strongly aligned to our charitable aim of advancing scientific discoveries that can improve human health.”
MRC Technology set up its CTD laboratories to support its technology transfer and IP management efforts, to bridge the gap between innovative, early stage academic research and the development of intellectual property suitable for licensing to industry, for further development and commercialisation. De-risking novel targets by providing proof of concept and pharma-quality data packages fulfils a clear need in the drug discovery process.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Researchers Fine-Tune Computer-Assisted Drug Repositioning Process to Treat Rare DiseasesNews
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition.READ MORE
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE